2007
DOI: 10.1111/j.1601-5215.2007.00217.x
|View full text |Cite
|
Sign up to set email alerts
|

The validity of the 21-item version of the Depression Anxiety Stress Scales as a routine clinical outcome measure

Abstract: The findings from the present study support the validity of DASS-21 as a routine clinical outcome measure in the private in-patient setting.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
215
3
2

Year Published

2012
2012
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 296 publications
(225 citation statements)
references
References 12 publications
5
215
3
2
Order By: Relevance
“…A total of 114 functional and behavioural assessments were completed across the 29 participants over the study time period and included for the analyses. Participants were included at baseline if (1) they fulfilled current criteria for svPPA or nfvPPA [1]; (2) had a reliable proxy informant to report on everyday functioning and behaviour (informants were judged reliable if they either lived with or regularly saw the patient, and if they were able to clearly articulate functional and behavioural information pertaining to the patient); (3) did not have any major physical impairment such as requiring mobility aids; (4) did not have major depressive symptoms as measured by the DASS-21 [11,12], and (5) had a longitudinal assessment within 18 months. People with a diagnosis of lvPPA were excluded from this study based on a combination of a neurological clinical assessment, neuropsychological data and in vivo β-amyloid imaging.…”
Section: Methodsmentioning
confidence: 99%
“…A total of 114 functional and behavioural assessments were completed across the 29 participants over the study time period and included for the analyses. Participants were included at baseline if (1) they fulfilled current criteria for svPPA or nfvPPA [1]; (2) had a reliable proxy informant to report on everyday functioning and behaviour (informants were judged reliable if they either lived with or regularly saw the patient, and if they were able to clearly articulate functional and behavioural information pertaining to the patient); (3) did not have any major physical impairment such as requiring mobility aids; (4) did not have major depressive symptoms as measured by the DASS-21 [11,12], and (5) had a longitudinal assessment within 18 months. People with a diagnosis of lvPPA were excluded from this study based on a combination of a neurological clinical assessment, neuropsychological data and in vivo β-amyloid imaging.…”
Section: Methodsmentioning
confidence: 99%
“…The longer DASS-42 and short-form DASS-21 were developed using Australian data and have been validated in both clinical and non-clinical samples (Antony et al, 1998;Henry and Crawford, 2005;Ng et al, 2007). The depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia; the anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect; and the stress scale assesses difficulty relaxing, nervous arousal, being easily upset/agitated, irritable/over-reactive and impatient.…”
Section: Assessment Of Depression Anxiety and Stressmentioning
confidence: 99%
“…Moderate level cut-offs (Depression ≥ 7, Anxiety ≥ 5, Stress ≥ 10) are representative of clinical populations (Lovibond & Lovibond, 1995;Ronk, Korman, Hooke, & Page, 2013). The instrument has good to excellent internal consistency (Cronbach's α = 0.82-0.94), good criterion validity, acceptable discriminant validity, moderate sensitivity to clinical change, and acceptable to good temporal stability (r = 0.71-0.81) in clinical samples (Antony et al, 1998;Brown, Chorpita, Korotitsch, & Barlow, 1997;Henry & Crawford, 2005;Ng et al, 2007;Page, Hooke, & Morrison, 2007).…”
Section: Methodsmentioning
confidence: 99%